Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Dec;62(6):988–991. doi: 10.1038/bjc.1990.422

Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?

M J Moore 1, B O'Sullivan 1, I F Tannock 1
PMCID: PMC1971580  PMID: 2257231

Abstract

In a previous study, urologists, radiation oncologists and medical oncologists in Britain, Canada and the United States were asked to state how they would wish to be treated if they had urologic cancer as described in six clinical scenarios and whether they would agree to be entered in randomised clinical trials. This study disclosed major controversy regarding treatment options for each scenario and reluctance by these experts to enter randomised clinical trials. In the present study a second questionnaire which included a summary of the treatments selected initially was sent to the same 227 oncologists. Respondents were asked, in view of these additional information, how they would wish to be treated and whether they would enter themselves (or their patients) on randomised trials comparing the two treatment options most favoured by their colleagues. Most respondents did not modify their treatment preference. There was still poor agreement to enter themselves on trials (29%), but a higher proportion would offer such trials to their patients (45%). Thus the demonstration of controversy about optimum treatment did not influence personal bias, but could facilitate the entry of patients into trials that address major controversies. We conclude that treatment strategies of urologic oncologists are influenced minimally by opinions of their colleagues, but that the method of using surrogate questionnaires is a valuable aid to the design of clinical trials.

Full text

PDF
988

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987 Jul 16;317(3):141–145. doi: 10.1056/NEJM198707163170304. [DOI] [PubMed] [Google Scholar]
  2. Mackillop W. J., O'Sullivan B., Ward G. K. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys. 1987 Jun;13(6):929–934. doi: 10.1016/0360-3016(87)90109-x. [DOI] [PubMed] [Google Scholar]
  3. Mackillop W. J., Palmer M. J., O'Sullivan B., Ward G. K., Steele R., Dotsikas G. Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br J Cancer. 1989 Mar;59(3):388–395. doi: 10.1038/bjc.1989.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Mackillop W. J., Ward G. K., O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer. 1986 Oct;54(4):661–667. doi: 10.1038/bjc.1986.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Moore M. J., O'Sullivan B., Tannock I. F. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol. 1988 Nov;6(11):1736–1745. doi: 10.1200/JCO.1988.6.11.1736. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES